Ildong Pharmaceutical and Ildong Holdings Introduce Interim Dividends... "Fostering New Businesses This Year"

Yoon Woong-seop, CEO of Ildong Pharmaceutical, is speaking at the Ildong Pharmaceutical regular shareholders' meeting in Seocho-gu, Seoul on the 26th. Photo by Ildong Pharmaceutical

IlDong Pharmaceutical and IlDong Holdings held their respective regular general meetings of shareholders on the 26th at IlDong Pharmaceutical headquarters in Seocho-gu, Seoul, and established a new article in the articles of incorporation regarding interim dividends.

IlDong Pharmaceutical announced that at the shareholders' meeting, all agenda items, including ▲ approval of financial statements ▲ partial amendment of the articles of incorporation ▲ appointment of directors and auditors, were approved as originally proposed.

The proposed amendment to the articles of incorporation included setting a record date and revising regulations on prior notice so that shareholders and investors can confirm dividends in advance and decide on investment, as well as the establishment of a clause regarding interim dividends.

Yoon Woong-seop, CEO of IlDong Pharmaceutical, introduced last year's performance improvements, the licensing out (technology transfer) of the new drug candidate 'P-CAB', and clinical progress of the 'GLP-1RA' candidate, stating, "This year, based on two key indicators?generating sales and profit performance, and securing new growth engines and establishing a sustainable system?we plan to increase profits through efficient business activities and also focus on discovering and nurturing new businesses."

Following this, IlDong Holdings' shareholders' meeting also approved all agenda items as originally proposed, including ▲ approval of financial statements ▲ partial amendment of the articles of incorporation including dividend-related regulations ▲ appointment of directors and auditors.

Park Dae-chang, Vice Chairman of IlDong Holdings, stated, "Based on performance creation, we plan to focus on enhancing the corporate value of the group and each affiliate, as well as improving shareholder benefits and building investor trust through the improvement of dividend policies and procedures."